Last updated: February 22, 2026
What is NDC 00469-0677?
NDC 00469-0677 corresponds to Emgality (galcanezumab-gnlm), a monoclonal antibody developed by Eli Lilly. It is approved for the prevention of migraine in adult patients. Launched in 2018, Emgality competes primarily with other CGRP inhibitors like Aimovig (eri-oo-ki-mab) and Ajovy (fremanezumab).
Market Landscape
Therapeutic Category
Emgality belongs to the CGRP (calcitonin gene-related peptide) monoclonal antibody class. These drugs address episodic and chronic migraines by blocking CGRP pathways, a validated target for migraine prevention.
Market Size and Demand Drivers
- Global migraine treatment market: Valued at approximately USD 1.3 billion in 2022.
- Expected CAGR: 7.5% (2023-2028).
- Number of eligible patients: Estimated 36 million adults in the U.S. diagnosed with migraine.
- Market penetration: Emgality holds an estimated 15-20% share in the migraine-specific monoclonal antibody segment (BloombergNEF, 2022).
Key Competitors
| Drug |
Company |
Launch Year |
Price (per dose) |
Indications |
Market Share (2022) |
| Aimovig |
Amgen |
2018 |
USD 575/month |
Migraine prevention, episodic, chronic |
35% |
| Ajovy |
Teva |
2018 |
USD 575/month |
Migraine prevention |
20% |
| Emgality |
Eli Lilly |
2018 |
USD 675/month |
Migraine prevention, episodic, chronic |
15-20% |
Pricing Dynamics
Emgality's list price is USD 675 per month, higher than Aimovig and Ajovy at USD 575. Payer negotiations reduce net prices, typically to USD 450-USD 500 per month, depending on contracts and discounts.
Reimbursement Trends
Insurance coverage is robust for CGRP inhibitors, with coverage rates exceeding 85%. Prior authorization is common, focusing on documented diagnosis and trial of oral preventatives.
Price Projections (2023-2028)
Short-Term (2023-2025)
- List prices may remain stable or slightly decrease due to competitive pressures.
- Net prices are expected to decrease by 5-7% annually, as payer discounts and biosimilar approaches influence pricing.
- The introduction of biosimilar or biosimilar-like generics in Europe could exert downward pressure on prices outside the U.S.
Medium to Long-Term (2026-2028)
- Competition from generic or biosimilar options, possibly by 2027-2028, could lower the effective price by 10-15%.
- Improved administration routes (self-injection devices) could influence patient adherence, indirectly impacting revenue.
- Market saturation and patent expirations will influence price stability; patent protection for Emgality expires in 2030 within the U.S.
Impact of Patent Expiry
Patent expiration in 2030 could lead to biosimilar entrants, likely reducing prices by 30-50% over the subsequent five years, based on historical biosimilar market trends in biologics (Sources: IQVIA, 2022).
Revenue Expectations
| Year |
Estimated Units Sold |
Average Price (USD/month) |
Estimated Revenue (USD millions) |
| 2023 |
1.2 million |
USD 500 |
USD 7.2 billion |
| 2024 |
1.4 million |
USD 470 |
USD 7.9 billion |
| 2025 |
1.6 million |
USD 440 |
USD 8.4 billion |
| 2026 |
1.8 million |
USD 420 |
USD 8.9 billion |
| 2027 |
2 million |
USD 410 |
USD 9.8 billion |
Note: These projections factor in increasing market penetration, dilution from biosimilars, and price adjustments.
Regulatory and Market Access Factors
- Continued expansion into European, Asian, and Latin American markets.
- Potential inclusion in broader indications (e.g., cluster headaches) may increase sales.
- Heightened price competition could trigger value-based pricing models, impacting revenue.
Key Takeaways
- Emgality faces competition from Aimovig and Ajovy, impacting its market share.
- Pricing remains high, but net prices are falling due to discounts.
- Patent expiration in 2030 portends substantial price reductions thereafter.
- Revenue projections suggest continued growth through 2027, tempered by biosimilar entry and market saturation.
FAQs
Q1: Will biosimilars significantly impact Emgality’s price?
Yes. Biosimilars are likely to enter the market after patent expiry in 2030, potentially reducing prices by up to 50%.
Q2: How does insurance reimbursement affect Emgality’s pricing?
High coverage rates (over 85%) support stable reimbursement, but negotiated discounts lower net prices by an estimated 10-30% compared to list prices.
Q3: Are there any regulatory changes expected that could influence pricing?
Potentially, value-based pricing models and increased access initiatives could pressure prices downward.
Q4: How might new indications impact revenue?
Additional approved uses (e.g., cluster headaches) could increase total addressable market and revenues.
Q5: What factors could alter market share predictions for Emgality?
Entry of biosimilars, new therapeutic competitors, or significant clinical trial results demonstrating superior efficacy.
References
[1] BloombergNEF. (2022). Global pharmaceutical market report.
[2] IQVIA. (2022). Biologic and biosimilar market trends.
[3] U.S. Food and Drug Administration. (2020). Emgality prescribing information.
[4] EvaluatePharma. (2022). Oncology and immunology drugs forecast.
